Analysis
Visit attendance was assessed at weeks 4, 12 and 24 among participants enrolled in the three trials. We excluded all participants who seroconverted and withdrew from the trial. We evaluated the proportion of participants selecting each DCP option at each scheduled visit, and the proportion of participants who ever selected PrEP and PEP during 24‐week follow‐up at each of the three settings. The proportion of follow‐up time covered by biomedical prevention (“biomedical covered time”) for a given participant was calculated as the number of months during which a participant reported PrEP or PEP use divided by the number of months for which self‐reported use was assessed. Participants who acquired HIV were assumed not to be covered during the period prior to seroconversion. “At risk” biomedical covered time was calculated analogously, but restricted to months for which a participant reported HIV risk. We report mean, median, first quartile (Q1) and third quartile (Q3) of both measures across participants.